Drug or chemical induced diabetes mellitus with ketoacidosis
ICD-10 E09.1 is a billable code used to indicate a diagnosis of drug or chemical induced diabetes mellitus with ketoacidosis.
Drug or chemical induced diabetes mellitus with ketoacidosis refers to a form of diabetes that arises as a direct consequence of the administration of certain medications or exposure to specific chemicals. This condition is characterized by hyperglycemia, insulin resistance, and the presence of ketoacidosis, which is a serious complication marked by the accumulation of ketones in the blood due to insufficient insulin. Common drugs that can induce this condition include glucocorticoids, antipsychotics, and certain chemotherapy agents. Patients may present with symptoms such as excessive thirst, frequent urination, nausea, abdominal pain, and altered mental status. Management typically involves the cessation of the offending agent, insulin therapy to control blood glucose levels, and monitoring for potential complications such as dehydration and electrolyte imbalances. The condition requires careful monitoring of HbA1c levels to assess long-term glucose control and prevent further complications associated with diabetes mellitus.
Detailed medication history, lab results, and management plans.
Patients presenting with new-onset diabetes after starting a new medication.
Endocrinologists must ensure that the cause of diabetes is clearly documented to support the use of E09.1.
Emergency department notes must include initial assessment, treatment provided, and follow-up care.
Patients presenting with diabetic ketoacidosis due to medication-induced diabetes.
Emergency physicians should document the timeline of medication use and onset of symptoms.
Used for follow-up visits for management of drug-induced diabetes.
Documentation must include assessment of diabetes control and medication review.
Endocrinologists should ensure comprehensive documentation of diabetes management.
Common drugs include glucocorticoids, certain antipsychotics, and some chemotherapy agents. Each can affect insulin secretion or action, leading to hyperglycemia.
